bioRxiv Science⌕ Search

Biology subjects

Venas, N.

Publications and source records attributed to Venas, N..

2 recordsLinked to original sources

GATA3-extension mutants rewire lineage identity in luminal breast cancer

GATA3, one of the most frequently mutated transcription factors in breast cancers, is a master regulator of luminal epithelial identity. Unlike many truncating and splice-site GATA3 mutations that disrupt one of the two zinc finger DNA-binding domains, C-terminal extension mutations (eGATA3) retain both of them. This raises the question of whether the eGATA3 mutants can alter transcriptional regulation and thereby exert distinct functional effects. Here, we integrate patient tumor-derived transcription and chromatin accessibility profiling with cell line derived genome-wide mapping of GATA3 occupancy and single-cell multiomics to define the regulatory consequences of eGATA3. We show that eGATA3 is associated with poor clinical outcome and remodels the luminal transcriptional program, leading to attenuation of estrogen-responsive transcription and progressive loss of luminal differentiation. Mechanistically, eGATA3 maintains widespread chromatin occupancy but redistributes GATA3 binding across different classes of regulatory elements, with preferential loss at AP-1 motif-enriched sites and gain at FOX-associated enhancers, along with coordinated remodeling of chromatin accessibility. These changes rewire the luminal regulatory landscape, destabilizing lineage identity without inducing complete lineage conversion. Together, our findings identify eGATA3 as a mechanistically distinct class of GATA3 mutation that promotes lineage plasticity through redistribution of genomic occupancy rather than loss of DNA-binding function alone.

cancer biology↗

Collective amoeboid dynamics drives colonization of drug-resistant ovarian cancer cells

Epithelial ovarian cancer (EOC) is characterized by resistance to platinum-based therapy, resulting in rapid progression and poor survival. Here, we ask whether drug resistance and invasiveness coevolve to drive metastasis. Selection experiments involving pulsed carboplatin exposure established isogenic chemoresistant variants of lines, which typify high-grade serous ovarian carcinoma (HGSOC), the most aggressive type of EOC. Time-lapse imaging showed enhanced migration of resistant single cells and their collectives. Resistant cell spheroids spread faster on Collagen I substrata than sensitive controls. The resistant OVCAR-3 transcriptome was ontologically enriched for migration and showed overlap with previously reported markers of resistance in EOC patients and other evolved lines. Gene set enrichment predicted transition between epithelial, mesenchymal, and amoeboid states is higher in resistance compared to control lines. Lower matrix adhesion, weak focal adhesion, and highly deformable and translatory dynamics of cell collectives indicated that resistant cancer cells displayed a unique collective amoeboid-like migration. When injected intraperitoneally into immunodeficient mice, resistant cells colonized to a greater extent on parietal mucosae. Ex vivo, suspended resistant cells formed moruloids associated with quicker peritoneal adhesion, clearing human coelomic mesothelial monolayers with higher efficiency. Knockdown in resistant OVCAR-3 cells of two upregulated proteins, E-cadherin and LGALS3BP, had distinct consequences. E-cadherin knockdown partially restored sensitivity to carboplatin but did not affect invasion. In contrast, silencing LGALS3BP decreased invasion but not resistance. Our results suggest that drug resistance and invasiveness could coevolve through the upregulation of distinct trait drivers in EOC.

cancer biology↗